WHITEGLOVEMD
Powered by Clintelligence™ AI
Thoracic oncology surgery — from lung resection and esophagectomy to mediastinal tumor excision — carries profound implications for survival, quality of life, and long-term function. The difference between a community hospital and a high-volume thoracic center can be the difference between cure and recurrence. A WhiteGloveMD review ensures your surgical plan reflects the best available evidence and the right team.
The most common form of lung cancer. Surgical options range from wedge resection to pneumonectomy depending on staging, location, and patient fitness. Minimally invasive approaches (VATS, robotic) offer faster recovery when anatomy permits. Our review evaluates staging accuracy, resectability, and whether neoadjuvant therapy should precede surgery.
Staging-dependentHistorically managed with chemotherapy and radiation, but emerging evidence supports surgical resection for limited-stage disease. Our review assesses whether you are a candidate for combined-modality therapy including surgical resection — a decision that requires specialized thoracic oncology expertise.
Urgent — rapid doubling timeEsophagectomy remains one of the most complex operations in thoracic surgery. The choice between transhiatal, Ivor Lewis, and McKeown approaches — and whether to proceed with upfront surgery vs. neoadjuvant chemoradiation — depends on tumor location, staging, and institutional expertise. Center volume is the single strongest predictor of operative mortality.
Multimodal planning criticalThymomas, thymic carcinomas, germ cell tumors, and neurogenic tumors of the mediastinum. Surgical approach, extent of resection, and need for adjuvant therapy depend on tumor type, size, and involvement of surrounding structures. Many patients benefit from a minimally invasive approach when performed at experienced centers.
Tissue diagnosis often neededMalignant pleural mesothelioma requires a highly specialized multidisciplinary approach. Options include extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D), combined with chemotherapy and potentially immunotherapy. Fewer than a dozen centers in the U.S. have meaningful volume in this disease.
Specialized center essentialSelected patients with limited metastatic disease to the lungs from colorectal, renal, sarcoma, or other primary cancers may benefit from surgical resection of pulmonary metastases. Patient selection is critical — our review evaluates disease-free interval, number and distribution of lesions, and primary tumor biology.
Patient selection criticalIndependent review of PET-CT, CT, and pathology to confirm clinical and pathological staging — the single most important factor in treatment planning.
Pulmonary function testing, cardiac risk assessment, performance status, and frailty evaluation to determine whether surgery is safe and appropriate.
Open thoracotomy vs. VATS vs. robotic-assisted resection. Extent of resection (wedge, segmentectomy, lobectomy, pneumonectomy). Lymph node dissection strategy.
Neoadjuvant vs. adjuvant chemotherapy and radiation timing. Immunotherapy eligibility. The sequence of treatments matters as much as the treatments themselves.
Volume-outcome data for your specific procedure. High-volume thoracic oncology centers have significantly better outcomes, particularly for esophagectomy and complex resections.
Biomarker testing (PD-L1, EGFR, ALK, ROS1, KRAS) and genomic profiling to ensure targeted therapy options are not missed before committing to surgery.
Decades of surgical outcomes data demonstrate that high-volume thoracic surgery centers have lower operative mortality, fewer complications, better long-term survival, and higher rates of minimally invasive approaches. Our review identifies the centers with the best documented outcomes for your specific procedure.
For esophagectomy, operative mortality at low-volume centers can exceed 10% compared to under 3% at high-volume centers. For complex lung resections, the gap in complication rates can be equally dramatic.
Our surgeon matching is not based on advertising or referral networks. It is based on publicly available volume and outcomes data — the same data that surgical quality organizations use to credential centers of excellence.
Get an independent, expert-level review of your thoracic oncology surgical plan — powered by AI analysis, delivered in 24 hours. Inaugural pricing from $495.